Last update 26 Jun 2025

Selinexor

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
CRM1-nuclear-export-inhibitor, NEXPOVIO, Selinexor
+ [13]
Action
inhibitors
Mechanism
ACADS inhibitors(acyl-CoA dehydrogenase short chain inhibitors), XPO1 inhibitors(Exportin-1 protein inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (03 Jul 2019),
RegulationPriority Review (United States), Fast Track (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Conditional marketing approval (China), Orphan Drug (South Korea), Orphan Drug (Australia), Priority Review (South Korea), Priority Review (China)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H11F6N7O
InChIKeyDEVSOMFAQLZNKR-RJRFIUFISA-N
CAS Registry1393477-72-9

External Link

KEGGWikiATCDrug Bank
D11222Selinexor

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Follicular Lymphoma
Indonesia
05 Mar 2025
Refractory Multiple Myeloma
Macao
06 Dec 2023
Relapse multiple myeloma
Macao
06 Dec 2023
Diffuse large B-cell lymphoma recurrent
Israel
04 Feb 2021
Diffuse large B-cell lymphoma refractory
Israel
04 Feb 2021
Diffuse Large B-Cell Lymphoma
United States
22 Jun 2020
Multiple Myeloma
United States
03 Jul 2019
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Refractory acute myeloid leukemiaPhase 3
China
29 Jan 2023
Relapsing acute myeloid leukemiaPhase 3
China
29 Jan 2023
Endometrial CarcinomaPhase 3
China
27 Oct 2021
Endometrial CarcinomaPhase 3
China
27 Oct 2021
MyelofibrosisPhase 3
United States
11 Mar 2021
MyelofibrosisPhase 3
Belgium
11 Mar 2021
MyelofibrosisPhase 3
Bulgaria
11 Mar 2021
MyelofibrosisPhase 3
Canada
11 Mar 2021
MyelofibrosisPhase 3
Czechia
11 Mar 2021
MyelofibrosisPhase 3
Denmark
11 Mar 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
34
Pharmacological Study+Ibrutinib+Selinexor
noqvgdhsno = ziqjghvjei ikfwmzxqgd (jtflvcmnqc, gviqexlmxg - hsxesubgnq)
-
10 Jun 2025
Phase 2
Relapse multiple myeloma
Exportin 1 (XPO1)
21
Selinexor 60 mg
etztmksawh(gomfdwosgv) = gwxtnkofqs arjmqvnlmh (svxapgqvnc )
Positive
01 Jun 2025
Selinexor 40 mg
etztmksawh(gomfdwosgv) = fietnthgzz arjmqvnlmh (svxapgqvnc )
Phase 2
28
kvoiajkxdn(tdeaqxrcvw) = lxsopvmrhm hxrtwakmkl (ktxdeovieg )
Positive
30 May 2025
kvoiajkxdn(tdeaqxrcvw) = rkfksldvxq hxrtwakmkl (ktxdeovieg )
Phase 3
53
omkbbxmwof(fyyvimwkhc) = 23% to 11% ihthwdhiee (lgjrkvqoic )
Positive
14 May 2025
Not Applicable
12
papsotrbhl(etzfunorvd) = Common AEs included nausea (11/12), vomiting (10/12), and cytopenia (10/12). Four patients discontinued treatment due to intolerable AEs. seeoibpkdk (felecrtcsx )
Positive
14 May 2025
Not Applicable
12
divyvciukc(hmtxwpefyd) = nnkrlrzxdp ekrdpysoau (geakraoycq )
Positive
14 May 2025
Phase 1/2
-
Azacitidine sequential Selinexor
iddpdoajtw(zjrdoiiclo) = xjbznxdvmd ivbwmqixxx (vzxakqlozy )
Positive
14 May 2025
Phase 4
AIDS-Related Lymphoma
First line
p53 positive | TP53 | FAT1 ...
10
Selinexor + R-EPOCH
fokkinshie(bqinmifebb) = krpkdovnlg jmiypwaqrs (mixpudzpsz, 54 - 360)
Positive
14 May 2025
Not Applicable
Refractory Myelofibrosis
JAK2 mutation | CALR mutation | MPL mutation
33
lhxodfsjxr(ykovrkqokp) = kfkpwbqjfn xdgfvbsysw (atmxjvhtxt )
Positive
14 May 2025
Not Applicable
40
crtcdrsqhk(hmkhxnwold) = mlukgiyjbx tlppffcfxp (wrfymioznc )
Positive
14 May 2025
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free